Aspen acquires anticoagulant brands


South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline (GSK). The £700 million deal includes Arixtra (fondaparinux) and Fraxiparine (nadroparin), as well as a manufacturing site in Notre-Dame de Bondeville, France.

Earlier this year, Aspen agreed a similarly large deal with MSD, the European subsidiary of Merck & Co, for a bundle of other drug brands and a manufacturing site in the Netherlands, which also produces heparin-based ingredients. ‘This deal presents excellent synergistic opportunities for Aspen’s ongoing global expansion strategy,’ said Aspen’s chief executive Stephen Saad in a statement. Together, the two deals will allow the firm to ‘pursue a more vertically integrated supply chain for heparin based products’.

GSK will retain distribution rights for the two drugs in China, Pakistan and India.

 


Related Content

Aspen in $1 billion deal with Merck

1 July 2013 Business

news image

South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker

Business roundup

27 January 2012 Business

news image

Industry news, February 2012

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Indian U-turn on diabetes drug ban

16 August 2013 News and Analysis

news image

Suspension of cheap and popular medicine reversed but will now come with new safety warnings

DNA waves don't wash

10 July 2013 The Crucible

news image

Philip Ball asks why a spectacular claim seems to have been overlooked. Sometimes science doesn’t work the way it’s suppo...